KalVista Pharmaceuticals Ownership | Who Owns KalVista Pharmaceuticals?
KalVista Pharmaceuticals Ownership Summary
KalVista Pharmaceuticals is owned by 84.66% institutional investors, 1.60% insiders, and 13.74% retail investors. Vr adviser is the largest institutional shareholder, holding 12.58% of KALV shares. American Funds SMALLCAP World A is the top mutual fund, with 5.56% of its assets in KalVista Pharmaceuticals shares.
KALV Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | KalVista Pharmaceuticals | 84.66% | 1.60% | 13.74% |
| Sector | Healthcare Stocks | 232.01% | 10.74% | -142.75% |
| Industry | Biotech Stocks | 381.47% | 10.55% | -292.02% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Vr adviser | 6.73M | 12.58% | $81.96M |
| Tang capital management | 5.04M | 9.42% | $61.41M |
| Frazier life sciences management | 5.04M | 9.42% | $61.39M |
| Suvretta capital management | 4.77M | 8.91% | $58.08M |
| Blackrock funding, inc. /de | 3.75M | 6.97% | $60.63M |
| Blackrock | 2.95M | 6.76% | $34.69M |
| Capital world investors | 2.81M | 5.21% | $45.36M |
| Vanguard group | 2.51M | 4.66% | $40.52M |
| Silverarc capital management | 2.43M | 4.50% | $39.20M |
| Tudor investment corp et al | 2.00M | 3.74% | $2.18M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Allostery investments lp | 40.00K | 5.76% | $452.20K |
| Silverarc capital management | 2.43M | 5.44% | $39.20M |
| Vr adviser | 6.73M | 4.61% | $81.96M |
| Tang capital management | 5.04M | 2.36% | $61.41M |
| Octagon capital advisors lp | 1.27M | 2.35% | $15.51M |
| Parkman healthcare partners | 1.74M | 2.20% | $21.13M |
| Sio capital management | 683.82K | 2.11% | $8.33M |
| Frazier life sciences management | 5.04M | 1.84% | $61.39M |
| Suvretta capital management | 4.77M | 1.49% | $58.08M |
| Dafna capital management | 422.73K | 1.27% | $5.15M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Tudor investment corp et al | 2.00M | 0.00% | 2.00M |
| Silverarc capital management | 2.43M | 5.44% | 1.06M |
| Parkman healthcare partners | 1.74M | 2.20% | 1.06M |
| Freestone grove partners lp | 704.45K | 0.06% | 704.45K |
| Sio capital management | 683.82K | 2.11% | 683.82K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Vestal point capital, lp | 750.00K | 0.41% | -3.92M |
| Tcg crossover management | - | - | -1.16M |
| Goldman sachs group | 835.30K | 0.00% | -964.88K |
| Ameriprise financial | 35.45K | 0.00% | -909.68K |
| Bioimpact capital | - | - | -896.91K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Tudor investment corp et al | 2.00M | 0.00% | 2.00M | $2.18M |
| Freestone grove partners lp | 704.45K | 0.06% | 704.45K | $8.58M |
| Sio capital management | 683.82K | 2.11% | 683.82K | $8.33M |
| Kynam capital management, lp | 606.17K | 0.55% | 606.17K | $7.38M |
| Hrt financial lp | 287.05K | 0.01% | 287.05K | $4.63M |
Sold Out
| Holder | Change |
|---|---|
| National bank of canada /fi/ | -1.00 |
| Nelson, van denburg & campbell wealth management group | -5.00 |
| Ifp advisors | -5.00 |
| Creekmur asset management | -23.00 |
| Corecap advisors | -23.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2025 | 128 | -15.79% | 45,617,570 | -22.20% | 84 | 0.70% | 72 | -7.69% | 37 | -5.13% |
| Sep 30, 2025 | 148 | 1.37% | 60,631,934 | 11.36% | 113 | 0.94% | 75 | -7.41% | 39 | 11.43% |
| Jun 30, 2025 | 145 | 5.07% | 54,415,240 | -0.92% | 109 | 1.01% | 80 | 12.68% | 35 | -7.89% |
| Mar 31, 2025 | 138 | 5.34% | 54,920,723 | -0.49% | 104 | 0.75% | 71 | -7.79% | 38 | 26.67% |
| Dec 31, 2024 | 126 | 0.80% | 48,891,669 | 0.99% | 104 | 0.95% | 71 | 4.41% | 31 | 3.33% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| American Funds SMALLCAP World A | 2.81M | 5.56% | -369.00K |
| Vanguard Total Stock Mkt Idx Inv | 1.35M | 2.67% | - |
| Vanguard US Total Market Shares ETF | 1.20M | 2.41% | - |
| APO Medical Opportunities R | 1.17M | 2.31% | 866.80K |
| International Biotechnology Ord | 1.16M | 2.29% | 506.51K |
| State Street® SPDR® S&P® Biotech ETF | 1.12M | 2.22% | -6.05K |
| MEDICAL BioHealth EUR Acc | 978.87K | 1.94% | 185.40K |
| iShares Russell 2000 ETF | 920.33K | 1.82% | 438.20K |
| apo Medical Opportunities R | 738.91K | 1.46% | 59.80K |
| SPDR® S&P Biotech ETF | 571.42K | 1.13% | 1.27K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Mar 09, 2026 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | $107.63K |
| Feb 23, 2026 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | $83.34K |
| Feb 23, 2026 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | $156.20K |
| Feb 23, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | $67.67K |
| Feb 23, 2026 | Sweeny Nicole | Chief Commercial Officer | Sell | $61.88K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q1 | - | 10 |
| 2025 Q4 | - | 10 |
| 2025 Q3 | - | 13 |
| 2025 Q2 | 1 | 9 |
| 2025 Q1 | 8 | 6 |
KALV Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools